GBA Presents: RADIO SAVANT-!
- Thread starter stonedinvestor
- Start date
RADIO SAVANT IS GOING OFF THE AIR FRI OR SAT.
... UPDATES ROLLING IN ON RAIN $3.8O IN CASH.. TWO CONFERENCES COMING UP IN NEXT SIX WEEKS WILL REVEAL TRIAL STUDY AT ONE OF THEM... EVERYTHING SOUNDS ON TARGET THIS TIME.. GET READY-!
Rain Oncology Inc. (RAIN)
NasdaqGS - NasdaqGS Real Time Price.
9.28+0.13 (+1.42%)
At close: 04:00PM EDT
9.68 +0.40 (+4.31%)
After hours: 04:18PM EDT
Rain Oncology Inc. (RAIN)
NasdaqGS - NasdaqGS Real Time Price.
9.28+0.13 (+1.42%)
At close: 04:00PM EDT
9.68 +0.40 (+4.31%)
After hours: 04:18PM EDT
Rain Oncology reports Q1 EPS (56c), consensus (61c) 16:28 RAIN
THIS CAME OUT TUES-
Portnoy says 'bought 2 million' in Penn Entertainment stock yesterday 15:43 PENN
Portnoy says 'bought 2 million' in Penn Entertainment stock yesterday 15:43 PENN
THIS CAME OUT MON-
Barclays 13F shows 'interesting' Constellation Brands buy, says Gordon Haskett 09:47
STZ
Gordon Haskett's head of event-driven research, Don Bilson, notes that Barclays kicked off the Q1 reporting season on Friday by having filed its 13F "more than a week early" and the firm highlights "some interesting positions," including what it calls "the most interesting of those" involving Constellation Brands. "What makes this juicy is it comes shortly after the Sands family executed a share-class exchange and as part of that, they ceded absolute control over the vote" and it would be "almost comical" if an activist "jumped on STZ the minute the family let down its guard," says the firm, which adds that it "wouldn't attach a high probability to this since the family still owns 14%."
Barclays 13F shows 'interesting' Constellation Brands buy, says Gordon Haskett 09:47
STZ
Gordon Haskett's head of event-driven research, Don Bilson, notes that Barclays kicked off the Q1 reporting season on Friday by having filed its 13F "more than a week early" and the firm highlights "some interesting positions," including what it calls "the most interesting of those" involving Constellation Brands. "What makes this juicy is it comes shortly after the Sands family executed a share-class exchange and as part of that, they ceded absolute control over the vote" and it would be "almost comical" if an activist "jumped on STZ the minute the family let down its guard," says the firm, which adds that it "wouldn't attach a high probability to this since the family still owns 14%."
RAIN CC IN 10 MINUTES---
10 MINUTES... DOUGIE FRESH YOU'RE ON....
Rain Oncology Inc.
– Quarter-end cash position of $110 million provides runway to complete all ongoing and planned clinical trials of milademetan, including the Phase 3 MANTRA trial in liposarcoma, Phase 2 MANTRA-2 basket trial, and planned Phase 1/2 MANTRA-4 basket trial –
– Required number of progression events achieved in the Phase 3 pivotal MANTRA trial to trigger the primary analysis of progression free survival (PFS) in patients with dedifferentiated liposarcoma (DDLPS) –
– Topline data for the MANTRA trial expected this quarter –
– Phase 2 MANTRA-2 trial continues to enroll across MDM2-amplified advanced solid tumor types –
– Phase 1/2 MANTRA-4 trial in advanced solid tumors exhibiting loss of the CDKN2A gene on track to commence in mid-2023 –
– Management to host conference call and webcast today at 5:00 PM Eastern Time –
NEWARK, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (Rain), a late-stage biotechnology company developing precision oncology therapeutics with a lead candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today reports financial results for the first quarter ended March 31, 2023, along with an update on the Company's key corporate highlights and upcoming milestones.
“We remain excited for MANTRA’s topline data readout, which we continue to anticipate in the second quarter. We are hopeful these data will support a potential new therapeutic option for patients with dedifferentiated liposarcoma, and also assert the importance of p53’s role in the regulation of cancer,” said Avanish Vellanki, co-founder and chief executive officer of Rain. “We continue to maintain strong fiscal prudence with tightly controlled cash burn on top of continued enrollment in MANTRA-2, and the anticipated, imminent start of the MANTRA-4 clinical trial.”
10 MINUTES... DOUGIE FRESH YOU'RE ON....
Rain Oncology Inc.
– Quarter-end cash position of $110 million provides runway to complete all ongoing and planned clinical trials of milademetan, including the Phase 3 MANTRA trial in liposarcoma, Phase 2 MANTRA-2 basket trial, and planned Phase 1/2 MANTRA-4 basket trial –
– Required number of progression events achieved in the Phase 3 pivotal MANTRA trial to trigger the primary analysis of progression free survival (PFS) in patients with dedifferentiated liposarcoma (DDLPS) –
– Topline data for the MANTRA trial expected this quarter –
– Phase 2 MANTRA-2 trial continues to enroll across MDM2-amplified advanced solid tumor types –
– Phase 1/2 MANTRA-4 trial in advanced solid tumors exhibiting loss of the CDKN2A gene on track to commence in mid-2023 –
– Management to host conference call and webcast today at 5:00 PM Eastern Time –
NEWARK, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (Rain), a late-stage biotechnology company developing precision oncology therapeutics with a lead candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today reports financial results for the first quarter ended March 31, 2023, along with an update on the Company's key corporate highlights and upcoming milestones.
“We remain excited for MANTRA’s topline data readout, which we continue to anticipate in the second quarter. We are hopeful these data will support a potential new therapeutic option for patients with dedifferentiated liposarcoma, and also assert the importance of p53’s role in the regulation of cancer,” said Avanish Vellanki, co-founder and chief executive officer of Rain. “We continue to maintain strong fiscal prudence with tightly controlled cash burn on top of continued enrollment in MANTRA-2, and the anticipated, imminent start of the MANTRA-4 clinical trial.”
IT'S BEEN QUIET ON THE ANALYST FRONT MIGHT WE GET A FEW RAIN UPGRADES TOMORROW.
NINE-ENDER IF YOU COULD COMMENT ON CRESCENT POINT ENERGY CPG-
MY SON HAS PICKED THIS OUT AS AN INVESTMENT IDEA.
MY SON HAS PICKED THIS OUT AS AN INVESTMENT IDEA.